ADXN vs AGMB

Addex Therapeutics Ltd vs AgomAb Therapeutics NV — Valuation Comparison 2026

ADXN

Biotechnology
Addex Therapeutics Ltd
Quality
5.5
out of 10
Value Trap
20
SAFE
Price
$6.82
Last close
Models
6/13
Active
VS

AGMB

Biotechnology
AgomAb Therapeutics NV
Quality
1.8
out of 10
Value Trap
Price
$11.54
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ADXN Fair ValueADXN Upside AGMB Fair ValueAGMB Upside
Bayesian DCF Intrinsic $3.06 -73.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $13.22 +88.8% $1.24 -89.2%
Dynamic NAV Asset-Based $6.04 -11.4% $8.88 -23.1%
PWERM Option-Based $13.95 +20.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADXN vs AGMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADXN vs AGMB — Which Stock Is More Undervalued?

ADXN scores higher with a 5.5/10 quality rating vs AGMB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Addex Therapeutics Ltd (ADXN) and AgomAb Therapeutics NV (AGMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADXN currently trades at $6.82 with a QOC of 5.5/10, while AGMB trades at $11.54 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).